Related Experiment Video
Updated: Jul 6, 2025
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy
Xinlin Liu1,2, Junwen Deng1,2, Renshuai Zhang1,2
1The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Abstract:
Despite the emergence of molecular targeted therapy and immune checkpoint inhibitors as standard first-line treatments for non-small cell lung cancer (NSCLC), their efficacy in some patients is limited by intrinsic and acquired resistance. Antibody-drug conjugates (ADCs), a revolutionary class of antitumor drugs, have displayed promising clinical outcomes in cancer treatment. In 2022, trastuzumab deruxtecan (Enhertu) was approved for treating HER2-mutated NSCLC, thereby underscoring the clinical value of ADCs in NSCLC treatment strategies. An increasing number of ADCs, focusing on NSCLC, are undergoing clinical trials, potentially positioning them as future treatment options. In this review, we encapsulate recent advancements in the clinical research of novel ADCs for treating NSCLC. Subsequently, we discuss the mechanisms of action, clinical efficacy, and associated limitations of these ADCs.
Insights
Antibody-drug conjugates (ADCs) show promise for non-small cell lung cancer (NSCLC) treatment, offering new options beyond current therapies. This review covers recent advancements, efficacy, and limitations of novel ADCs in NSCLC clinical research.
Area of Science:
- Oncology
- Pharmacology
Background:
- Standard non-small cell lung cancer (NSCLC) treatments like targeted therapy and immune checkpoint inhibitors face challenges due to intrinsic and acquired resistance.
- Antibody-drug conjugates (ADCs) represent a significant advancement in cancer therapeutics, demonstrating notable clinical success.
- The 2022 approval of trastuzumab deruxtecan for HER2-mutated NSCLC highlights the therapeutic potential of ADCs in this disease.
Purpose of the Study:
- To review recent clinical research on novel antibody-drug conjugates (ADCs) for non-small cell lung cancer (NSCLC).
- To discuss the mechanisms of action, clinical efficacy, and limitations of emerging ADCs in NSCLC treatment.
Main Methods:
- Literature review of recent clinical trials and studies involving ADCs for NSCLC.
- Analysis of data on ADC mechanisms, efficacy, and safety profiles.
Main Results:
- Trastuzumab deruxtecan's approval signifies a breakthrough for ADCs in HER2-mutated NSCLC.
- Numerous ADCs are in clinical trials, indicating a growing pipeline of potential NSCLC treatments.
- ADCs offer a promising alternative or addition to existing NSCLC treatment strategies.
Conclusions:
- ADCs are emerging as a vital therapeutic class for non-small cell lung cancer.
- Ongoing clinical trials are crucial for evaluating the future role of novel ADCs in NSCLC management.
- Understanding ADC mechanisms, efficacy, and limitations is key to optimizing their use in NSCLC treatment.
More Related Videos
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
